Navegando por Palavras-chave "branch retinal vein occlusion"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up
    (Lippincott Williams & Wilkins, 2008-02-01) Wu, Lihteh; Arevalo, Jose Fernando; Roca, Jose Antonio; Maia, Mauricio [UNIFESP]; Berrocal, Maria Hortensia; Rodriguez, Francisco J.; Evans, Teodoro; Costa, Rogerio Alves [UNIFESP]; Cardillo, José Augusto [UNIFESP]; PACORES; Inst Cirugia Ocular; Clin Oftalmol Ctr; Clin Ricardo Palma; Universidade Federal de São Paulo (UNIFESP); Univ Puerto Rico; Univ Rosario; Hosp Olhos Araraquara
    Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months
    (Lippincott Williams & Wilkins, 2009-11-01) Wu, Lihteh; Arevalo, Jose Fernando; Berrocal, Maria Hortensia; Maia, Mauricio [UNIFESP]; Roca, Jose Antonio; Morales-Canton, Virgilio; Alezzandrini, Arturo A.; Diaz-Llopis, Manuel Jose; Inst Cirugia Ocular; Ctr Caracas; Univ Puerto Rico; Universidade Federal de São Paulo (UNIFESP); Clin Ricardo Palma; Hosp Luis Sanchez Bulnes; Univ Buenos Aires; Inst Oftalmol Valencia
    Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion.Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months.Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 +/- 0.63 (P < 0.0001) units to 0.64 +/- 0.6 units for the 2.5-mg group (P < 0.0001). In the 1.25-mg group, 26 (68%) eyes gained >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 +/- 140 mu m to 244 +/- 125 mu m (P < 0.0001) versus 444 +/- 175 mu m to 234 +/- 80 mu m in the 2.5-mg group (P < 0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported.Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA. RETINA 29:1396-1403, 2009